WMT

122.66

+1.92%↑

COST

973.89

+0.33%↑

PG

144.84

+0.7%↑

KO

75.55

+1.04%↑

PM

163.85

-0.26%↓

WMT

122.66

+1.92%↑

COST

973.89

+0.33%↑

PG

144.84

+0.7%↑

KO

75.55

+1.04%↑

PM

163.85

-0.26%↓

WMT

122.66

+1.92%↑

COST

973.89

+0.33%↑

PG

144.84

+0.7%↑

KO

75.55

+1.04%↑

PM

163.85

-0.26%↓

WMT

122.66

+1.92%↑

COST

973.89

+0.33%↑

PG

144.84

+0.7%↑

KO

75.55

+1.04%↑

PM

163.85

-0.26%↓

WMT

122.66

+1.92%↑

COST

973.89

+0.33%↑

PG

144.84

+0.7%↑

KO

75.55

+1.04%↑

PM

163.85

-0.26%↓

Search

Ambev SA

Open

BrancheKonsumgüter defensiv

2.79 -0.36

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.74

Max

2.82

Schlüsselkennzahlen

By Trading Economics

Einkommen

-517M

4.3B

Verkäufe

4B

25B

KGV

Branchendurchschnitt

15.263

28.772

Dividendenrendite

10.72

Gewinnspanne

17.521

Angestellte

39,000

EBITDA

-1.6B

5.9B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+11.43% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

10.72%

3.67%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-3.3B

45B

Vorheriger Eröffnungskurs

3.15

Vorheriger Schlusskurs

2.79

Nachrichtenstimmung

By Acuity

34%

66%

36 / 131 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Ambev SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. März 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. März 2026, 22:55 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. März 2026, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. März 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. März 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. März 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. März 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. März 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. März 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. März 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. März 2026, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. März 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. März 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. März 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. März 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. März 2026, 21:10 UTC

Wichtige Nachrichtenereignisse

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. März 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk
Ergebnisse
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Ambev SA Prognose

Kursziel

By TipRanks

11.43% Vorteil

12-Monats-Prognose

Durchschnitt 3.12 USD  11.43%

Hoch 4 USD

Tief 2.35 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ambev SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

3 ratings

1

Buy

1

Halten

1

Sell

Technischer Score

By Trading Central

2.49 / 2.54Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

36 / 131 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ambev SA

Ambev S.A., through its subsidiaries, engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, malt and food, other alcoholic beverages, and non-alcoholic and non-carbonated products in Brazil, Central America and Caribbean, Latin America South, and Canada. It offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Budweiser, Bud Light, Beck, Leffe, Hoegaarden, Balboa ICE, Balboa, Atlas Golden Light, Atlas, Bucanero, Cristal, Mayabe, Presidente, Presidente Light, Brahma Light, Bohemia, The One, Corona, Modelo Especial, Stella Artois, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Michelob Ultra, Busch, Pilsen, Ouro Fino, Bud 66, Banks, Deputy, Patricia, Labatt Blue, Alexander Keith's, and Kokanee brands. The company also provides carbonated soft drinks, bottled water, isotonic beverages, energy drinks, coconut water, powdered and natural juices, and ready-to-drink teas under the Guaraná Antarctica, Gatorade, H2OH!, Pepsi Black, Lipton Iced Tea, Fusion, Pepsi-Cola, Canada Dry, Squirt, Red Rock, Red Bull, Seven Up, Nutrl, Bud Light Seltzer, Palm Bay, and Mike's brands. It offers its products through a network of third-party distributors and a direct distribution system. The company was founded in 1885 and is headquartered in São Paulo, Brazil. Ambev S.A. is a subsidiary of Interbrew International B.V.
help-icon Live chat